{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:15:16Z","timestamp":1787022916557,"version":"build-2736575974"},"reference-count":17,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:p>Pediatric emergency departments (EDs) in the United States are facing a rise in the number of children and adolescents who present with opioid use disorder (OUD), often driven by illicitly manufactured fentanyl. Medication treatment of pediatric OUD in the ED setting is often limited to symptomatic treatment of opioid withdrawal. Pediatric patients are rarely offered medications for OUD, especially in the ED setting. Buprenorphine is a partial opioid agonist that is Food and Drug Administration\u2013approved for the treatment of OUD in patients aged 16 years and older. Adult studies have demonstrated that ED initiation of medication for OUD such as buprenorphine is feasible, safely treats withdrawal symptoms, and can improve patient compliance with outpatient follow-up. However, initiation of buprenorphine in the ED has not been well-studied in the pediatric population. We present 2 cases of adolescent patients, a 16-year-old male and 17-year-old female, who presented to the ED with opioid withdrawal. They were both diagnosed with severe OUD because of their use of counterfeit pills containing fentanyl. Both patients were successfully started on buprenorphine\/naloxone in the pediatric ED before transitioning to an outpatient addiction clinic for continued treatment. The case series demonstrates the feasibility of ED-based buprenorphine initiation for adolescents, an important and timely intervention for adolescents with OUD.<\/jats:p>","DOI":"10.1542\/peds.2024-066226","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T04:11:48Z","timestamp":1720152708000},"source":"Crossref","is-referenced-by-count":8,"title":["Initiation of Buprenorphine Treatment of Opioid Use Disorder in Pediatric Emergency Departments"],"prefix":"10.1542","volume":"154","author":[{"given":"Prianka","family":"Kumar","sequence":"first","affiliation":[{"name":"aSchool of Medicine and Health Sciences and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivabalaji","family":"Kaliamurthy","sequence":"additional","affiliation":[{"name":"bDepartment of Psychiatry, George Washington University, Washington, District of Columbia"},{"name":"Divisions of cChild and Adolescent Psychiatry"},{"name":"dDepartment of Psychiatry, Howard University, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Thomas","sequence":"additional","affiliation":[{"name":"eEmergency Medicine, Children\u2019s National Hospital, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2024,7,5]]},"reference":[{"key":"2024080102532578300_B1","unstructured":"Centers for Disease Control and Prevention. CDC Wonder. Available at: http:\/\/wonder.cdc.gov\/. Accessed January 9, 2024"},{"issue":"2","key":"2024080102532578300_B2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1056\/NEJMp2312084","article-title":"The overdose crisis among U.S. adolescents","volume":"390","author":"Friedman","year":"2024","journal-title":"N Engl J Med"},{"issue":"50","key":"2024080102532578300_B3","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.15585\/mmwr.mm7150a2","article-title":"Drug overdose deaths among persons aged 10\u201319 years - United States, July 2019\u2013December 2021","volume":"71","author":"Tanz","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"2024080102532578300_B4","first-page":"524","article-title":"The impact of pediatric opioid-related visits on U.S. emergency departments","volume":"9","author":"Champagne-Langabeer","year":"2022","journal-title":"Children (Basel)"},{"issue":"1","key":"2024080102532578300_B5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12954-022-00634-4","article-title":"\u201cThey say it\u2019s fentanyl, but they honestly look like Perc 30s\u201d: initiation and use of counterfeit fentanyl pills","volume":"19","author":"Daniulaityte","year":"2022","journal-title":"Harm Reduct J"},{"issue":"2","key":"2024080102532578300_B6","doi-asserted-by":"crossref","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2024080102532578300_B7","doi-asserted-by":"crossref","first-page":"e223821","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2024080102532578300_B8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13722-022-00339-w","article-title":"Attitudes and training related to substance use in pediatric emergency departments","volume":"17","author":"Hoch","year":"2022","journal-title":"Addict Sci Clin Pract"},{"issue":"4","key":"2024080102532578300_B9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1001\/jamapediatrics.2023.6493","article-title":"Treating adolescent opioid use disorder in primary care","volume":"178","author":"Hadland","year":"2024","journal-title":"JAMA Pediatr"},{"issue":"2","key":"2024080102532578300_B10","doi-asserted-by":"crossref","first-page":"e2022058755","DOI":"10.1542\/peds.2022-058755","article-title":"Buprenorphine dispensing among youth aged \u226419 years in the United States: 2015\u20132020","volume":"151","author":"Terranella","year":"2023","journal-title":"Pediatrics"},{"issue":"4","key":"2024080102532578300_B11","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jadohealth.2020.03.005","article-title":"Adolescent-serving addiction treatment facilities in the United States and the availability of medications for opioid use disorder","volume":"67","author":"Alinsky","year":"2020","journal-title":"J Adolesc Health"},{"issue":"22","key":"2024080102532578300_B12","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1001\/jama.2023.6266","article-title":"Treatments used among adolescent residential addiction treatment facilities in the US, 2022","volume":"329","author":"King","year":"2023","journal-title":"JAMA"},{"key":"2024080102532578300_B13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\u201cEverything is not right anymore\u201d: buprenorphine experiences in an era of illicit fentanyl","volume":"74","author":"Silverstein","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"6","key":"2024080102532578300_B14","doi-asserted-by":"crossref","first-page":"e2314925","DOI":"10.1001\/jamanetworkopen.2023.14925","article-title":"Estimated reductions in opioid overdose deaths with sustainment of public health interventions in 4 US states","volume":"6","author":"Chhatwal","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2024080102532578300_B15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/17512433.2019.1635454","article-title":"Buprenorphine treatment for opioid use disorder: recent progress","volume":"12","author":"Parida","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"2024080102532578300_B16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.15585\/mmwr.mm7306a2","article-title":"Routes of drug use among drug overdose deaths - United States, 2020\u20132022","volume":"73","author":"Tanz","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"2024080102532578300_B17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.15288\/jsad.2019.80.393","article-title":"Medications for maintenance treatment of opioid use disorder in adolescents: a narrative review and assessment of clinical benefits and potential risks","volume":"80","author":"Camenga","year":"2019","journal-title":"J Stud Alcohol Drugs"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2024-066226\/1685369\/peds.2024-066226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2024-066226\/1685369\/peds.2024-066226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T23:00:48Z","timestamp":1722466848000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/154\/2\/e2024066226\/197674\/Initiation-of-Buprenorphine-Treatment-of-Opioid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,7,5]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2024-066226","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]},"article-number":"e2024066226"}}